Related Experiment Video

Updated: Feb 23, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.4K

Identification of WEE1 as a target to make AKT inhibition more effective in melanoma

Omer F Kuzu1, Raghavendra Gowda1,2,3, Arati Sharma1

  • 1a The Pennsylvania State University College of Medicine , Department of Pharmacology , Hershey , PA.

Cancer Biology & Therapy
|August 31, 2017
PubMed

Insights

Targeting AKT3 and WEE1 kinases together significantly enhances melanoma treatment efficacy. This combined approach synergistically inhibits melanoma cell viability and reduces tumor development by modulating p53 and FOXM1 pathways.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • AKT3 is a key therapeutic target in melanoma, but monotherapy shows limited clinical efficacy.
  • Identifying novel strategies to potentiate AKT3 inhibition is crucial for effective melanoma treatment.

Purpose of the Study:

  • To discover unique therapeutic strategies for enhancing AKT3 targeting in melanoma.
  • To identify potent co-targets that synergize with AKT3 inhibition in melanoma.

Main Methods:

  • A kinase inhibitor screen was performed to identify targets co-inhibiting effectively with AKT3.
  • RNA interference (RNAi) was used to mediate the inhibition of AKT3 and WEE1.
  • Melanoma cell viability and tumor development were assessed following combined inhibition.

Main Results:

  • WEE1 was identified as the most potent co-target, significantly enhancing AKT3 inhibition efficacy.
  • Combined RNAi-mediated inhibition of AKT3 and WEE1 synergistically reduced melanoma cell viability by 65-75%.
  • This synergistic effect was mechanistically linked to the modulation of p53 and FOXM1 transcription factor pathways.

Conclusions:

  • Co-targeting AKT3 and WEE1 presents a promising therapeutic strategy to improve AKT3-targeted therapy in melanoma.
  • Simultaneous regulation of p53 and FOXM1 pathways by combined AKT3 and WEE1 inhibition leads to synergistic cancer cell death.
  • This study offers a novel approach to overcome therapeutic resistance and enhance treatment outcomes in melanoma.
Keywords:
AKT3MelanomaWEE1synergy

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K